Oct 21st 2013 - Edison Investment Research today published a report on quickview entitled "Expanded Portfolio". In summary, the report says:
Mesoblast’s acquisition of Osiris’s culture-expanded MSC business consolidates its position as the leading mesenchymal stem cell development company. For a relatively modest initial consideration of US$50m, Osiris adds a complementary stem cell platform, two Phase III programmes with near-term revenue potential and a Japanese partnership. Mesoblast’s A$1.5bn EV underplays its pipeline potential (six programmes in Phase III in 2014) and the value of its strategic partnerships.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »